Florida-based startup Transpire Bio announced that it has signed an agreement with Recipharm for development of two inhaled candidates, TRB-1 and TRB-2, for the treatment of asthma and COPD. The company says that the two generic MDIs are "intended for advanced markets." Transpire CEO Xian-Ming Zeng said, "Our mission is to improve access to important, life-saving … [Read more...] about Recipharm to develop two inhalation formulations for Transpire Bio
Business
VisionHealth says Boehringer Ingelheim to cooperate on distribution of the Kata inhaler training app in Germany
German digital health company VisionHealth has announced that it will "cooperate on distribution of inhalation platform Kata" with Boehringer Ingelheim in Germany. The Kata app uses artificial intelligence and augmented reality technology in conjunction with the patient's smartphone camera to provide interactive inhaler use coaching. The company says that the app can … [Read more...] about VisionHealth says Boehringer Ingelheim to cooperate on distribution of the Kata inhaler training app in Germany
TFF Pharmaceuticals expands with new R&D facility
TFF Pharmaceuticals announced that it has leased a new 3,500+ square foot R&D facility in Austin, Texas, USA, that will house additional lab space, as well as equipment for the production of preclinical supplies, significantly expanding the company's capabilities. TFF also said that it will continue its relationship with the University of Texas at Austin, where … [Read more...] about TFF Pharmaceuticals expands with new R&D facility
Theravance, Innoviva selling Trelegy Ellipta royalty interests to Royalty Pharma
According to Theravance Biopharma, the company is selling its stake in Theravance Respiratory Company (TRC), which received royalties from sales of GSK's Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol DPI. The deal with Royalty Pharma is worth up to $1.5 billion, including $1.1 billion up front, the company said. Theravance Biopharma owns 85% of TRC; … [Read more...] about Theravance, Innoviva selling Trelegy Ellipta royalty interests to Royalty Pharma
NurExone partners with Polyrizon for development of intranasal therapy for spinal cord injuries
Israeli startup NurExone Biologic has announced that it will pay Israeli nasal delivery specialist Polyrizon a total of up to $3,350,000 for development of an intranasal formulation of NurExone's ExoTherapy, exosomes loaded with modified siRNA sequences for the treatment of traumatic spinal cord injuries. The formulation will be based on Polyrizon's Trap and Target … [Read more...] about NurExone partners with Polyrizon for development of intranasal therapy for spinal cord injuries
Bayer launches Astepro Allergy nasal spray in the US
Bayer said that its Astepro Allergy azelastine nasal spray is now available over the counter in US retail stores for the treatment of respiratory allergy symptoms in people aged 6 and older. The FDA approved Astepro Allergy for nonprescription use in June 2021. Bayer Consumer Health US VP and General Manager of Upper Respiratory Catherine Vennat said, "At Bayer, … [Read more...] about Bayer launches Astepro Allergy nasal spray in the US
Padagis launches generic of Narcan naloxone nasal spray
Padagis, formerly Perrigo's generic prescription pharmaceutical business, has announced the launch of a generic version of Narcan naloxone nasal spray for the reversal of opioid overdose. The Padagis generic is the second approved in the US since the FDA's initial approval of Narcan in 2015. Teva’s version of Narcan was approved by the FDA in April 2019 and was … [Read more...] about Padagis launches generic of Narcan naloxone nasal spray
Glenmark launches Indamet indacaterol / mometasone DPI for the treatment of asthma in India
Glenmark Pharmaceuticals has announced the launch of an inhaled dry powder fixed dose combination of indacaterol and mometasone furoate for the treatment of asthma which is being marketed under the name "Indamet". All three of the strengths offered include 150 mcg of indacaterol, plus either 80, 160, or 320 mcg of mometasone. Glenmark Group VP and Head, India … [Read more...] about Glenmark launches Indamet indacaterol / mometasone DPI for the treatment of asthma in India
Esteve Pharmaceuticals launches Inbrija levodopa DPI in Germany
Acorda Therapeutics announced that Inbrija levodopa inhalation powder has been launched in Germany by Esteve Pharmaceuticals. The EMA approved Inbrija DPI for the treatment of OFF periods in Parkinson’s disease in 2019. Acorda said that Esteve will pay "a significant double-digit percent of the selling price" plus sales based milestone payments. In July 2021, … [Read more...] about Esteve Pharmaceuticals launches Inbrija levodopa DPI in Germany
Opiant invests €2 million for expanded production of Aptar nasal device for use with OPNT003
Opiant Pharmaceuticals announced that it has signed an agreement with Aptar Pharma for expanded production of Aptar’s Unidose device in order to support potential commercial demand for Opiant's OPNT003 intranasal nalmefene. The agreement includes €2 million from Opiant for installation of the necessary production equipment. Opiant recently initiated a rolling NDA … [Read more...] about Opiant invests €2 million for expanded production of Aptar nasal device for use with OPNT003